Abstract
Why, with all the progress in the field of neurodegeneration, do we still lack disease-modifying drugs that tackle the primary defect of severe cell loss? How much progress has been made toward this goal? Have we spent our time and resources wisely? And, most important, is there room for improvement? This commentary highlights several problems faced by researchers in studying the genetic etiology of neurodegenerative diseases and seeks to provide direction in overcoming some of these obstacles.
References
St. George-Hyslop, P. et al. Nat. Genet. 2, 330–334 (1992).
St. George-Hyslop, P. et al. Science 235, 885–890 (1987).
Goate, A. et al. Nature 349, 704–706 (1991).
Sherrington, R. et al. Nature 375, 754–760 (1995).
Van Broeckhoven, C. et al. Nat. Genet. 2, 335–339 (1992).
Levy-Lahad, E. et al. Science 269, 973–977 (1995).
Rogaev, E.I. et al. Nature 376, 775–778 (1995).
Van Broeckhoven, C. et al. Science 248, 1120–1122 (1990).
Bertram, L. & Tanzi, R.E. Hum. Mol. Genet. 13 Spec No 1, R135–R141 (2004).
Corder, E.H. et al. Science 261, 921–923 (1993).
Sleegers, K. et al. Trends Genet. 26, 84–93 (2010).
Harold, D. et al. Nat. Genet. 41, 1088–1093 (2009).
Lambert, J.C. et al. Nat. Genet. 41, 1094–1099 (2009).
Van Deerlin, V.M. et al. Nat. Genet. 42, 234–239 (2010).
Teslovich, T.M. et al. Nature 466, 707–713 (2010).
Lambert, J.C. et al. J. Alzheimers Dis. 20, 1107–1118 (2010).
Jones, L. et al. Alzheimers Dement. 6, S113 (2010).
Aisen, P.S. Lancet Neurol. 1, 279–284 (2002).
Trompet, S. et al. J. Neurol. 257, 85–90 (2010).
Yerbury, J.J. et al. FASEB J. 21, 2312–2322 (2007).
Kauwe, J.S. et al. J. Alzheimers Dis. published online, 10.3233/JAD-2010-091711 (15 July 2010).
Potkin, S.G. et al. PLoS One 4, e6501 (2009).
Shulman, J.M. et al. PLoS One 5, e11244 (2010).
Rademakers, R. et al. Hum. Mutat. 22, 409–411 (2003).
Dermaut, B. et al. Ann. Neurol. 55, 617–626 (2004).
Sleegers, K., Cruts, M. & Van Broeckhoven, C. Annu. Rev. Neurosci. 33, 71–88 (2010).
Bettens, K., Sleegers, K. & Van Broeckhoven, C. Hum. Mol. Genet. 19, R4–R11 (2010).
Baker, M. et al. Nature 442, 916–919 (2006).
Cruts, M. et al. Nature 442, 920–924 (2006).
Van Deerlin, V.M. et al. Lancet Neurol. 7, 409–416 (2008).
Sreedharan, J. et al. Science 319, 1668–1672 (2008).
Kabashi, E. et al. Nat. Genet. 40, 572–574 (2008).
Kwiatkowski, T.J. Jr. et al. Science 323, 1205–1208 (2009).
Vance, C. et al. Science 323, 1208–1211 (2009).
Rademakers, R. et al. Am. J. Hum. Genet. 77, 643–652 (2005).
Sleegers, K. & Van Broeckhoven, C. Nature 458, 415–417 (2009).
Brouwers, N. et al. Neurology 71, 656–664 (2008).
van der Zee, J. et al. Hum. Mutat. 28, 416 (2007).
Sleegers, K. et al. Ann. Neurol. 65, 603–609 (2009).
Zuchner, S., Beecham, G., Haines, J. & Pericak-Vance, M.A. Alzheimers Dement. 6, S74 (2010).
Di Fede, G. et al. Science 323, 1473–1477 (2009).
Tomiyama, T. et al. Ann. Neurol. 63, 377–387 (2008).
Clarimón, J. et al. Neurobiol. Aging 30, 1986–1991 (2009).
Nalls, M.A. et al. Neurogenetics 10, 183–190 (2009).
Nuytemans, K., Theuns, J., Cruts, M. & Van Broeckhoven, C. Hum. Mutat. 31, 763–780 (2010).
Rovelet-Lecrux, A. et al. Nat. Genet. 38, 24–26 (2006).
Rovelet-Lecrux, A. et al. J. Alzheimers Dis. published online, 10.3233/JAD-2010-100441 (15 July 2010).
Gijselinck, I. et al. Hum. Mutat. 29, 53–58 (2008).
Theuns, J. et al. Am. J. Hum. Genet. 78, 936–946 (2006).
Beecham, G.W. et al. Alzheimers Dement. 6, S113 (2010).
Acknowledgements
A number of the issues identified in this commentary were discussed in a session on genetics at the Herrenhausen Symposium on Neurodegeneration with P. St. George-Hyslop, P. Heutink and B. De Strooper, with added discussion points and commentary provided by the attendees at the conference. The research in my group has been funded by the Flemish and Federal governments of Belgium, the VIB, the Institute Born-Bunge and the University of Antwerp, as well as by many national and international governmental research funding agencies and charity organizations. The main contributors, however, are the many people with neurodegenerative disease and their families that generously participate in research and the efforts of researchers to pave the way toward new therapeutics.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Van Broeckhoven, C. The future of genetic research on neurodegeneration. Nat Med 16, 1215–1217 (2010). https://doi.org/10.1038/nm.2225
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2225
- Springer Nature America, Inc.
This article is cited by
-
Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing
Scientific Reports (2019)
-
Con: Alzheimer's disease and circadian dysfunction: chicken or egg?
Alzheimer's Research & Therapy (2012)
-
Multiplexed protein detection using an affinity aptamer amplification assay
Analytical and Bioanalytical Chemistry (2012)
-
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders
Nature Reviews Neuroscience (2011)
-
Neurodegeneration and the neuroimmune system
Nature Medicine (2010)